IKZF1 and IKZF3: Unlocking New Keys to Immunology and Tumor Therapy

IKZF1 and IKZF3

IKZF1 and IKZF3: Unlocking New Keys to Immunology and Tumor Therapy

In the fields of immunology and tumor therapy, IKZF1 (Ikaros) and IKZF3 (Aiolos) are emerging as research hotspots. They are not only critical transcription factors but also play important roles in regulating immune cell function and tumor cell proliferation.

IKZF1 and IKZF3: Key Regulatory Factors in Immunology and Tumors

IKZF1 and IKZF3 belong to the Ikaros family of proteins, which are transcription factors with highly conserved zinc finger structures. They exert pleiotropic effects in various immune cells, particularly in the differentiation and proliferation of lymphocytes. For example, IKZF1 is involved in the regulation of interleukin-2 (IL-2) expression, affecting T cell activation and proliferation; whereas IKZF3 plays a leading role in the middle to late stages of B cell differentiation and maturation.

In the tumor field, the abnormal expression of IKZF1 and IKZF3 is closely related to the occurrence and development of various hematological malignancies. For instance, the overexpression of IKZF1 and IKZF3 in multiple myeloma (MM) leads to the massive proliferation of malignant plasma cells. Therefore, the development of drugs targeting IKZF1 and IKZF3 provides new strategies for treating various hematological malignancies and autoimmune diseases.

Targeted Therapy for IKZF1 and IKZF3

In recent years, significant progress has been made in the development of drugs targeting IKZF1 and IKZF3. Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide induce the degradation of IKZF1 and IKZF3 by binding to cereblon (CRBN) E3 ubiquitin ligase, thereby exerting anti-tumor and immunomodulatory effects. However, the efficacy of these drugs in treating relapsed/refractory tumors is limited, and there remains an unmet clinical need.

1. Molecular Glue Degraders (CELMoDs)

CELMoDs (Cereblon E3 Ligase Modulators) are a new class of thalidomide analogs that can degrade IKZF1 and IKZF3 more effectively. Compared with traditional IMiDs, CELMoDs have higher binding affinity and specificity, enabling deeper degradation of target proteins. Currently, multiple CELMoDs compounds have entered clinical research stages, showing good in vitro and in vivo activity.

• CC-92480: The first CELMoD to enter clinical trials, demonstrating good anti-tumor activity and tolerability.
• CC-220 (Iberdomide): Showing potential clinical efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM) and systemic lupus erythematosus (SLE).
• CC-99282: Demonstrating a high response rate in the treatment of relapsed/refractory non-Hodgkin's lymphoma (R/R NHL).
• CFT-7455: A new generation of CELMoDs with higher biological activity and a longer half-life, but attention should be paid to its side effects.

2. PROTACs Technology

PROTACs (Proteolysis Targeting Chimeras) are a class of small molecule drugs that degrade target proteins through the proteasome. Studies have shown that PROTACs can recognize numerous tumor targets, including IKZF1 and IKZF3. For example, certain CRBN-based PROTACs can efficiently degrade IKZF1 and IKZF3, thereby inhibiting tumor cell proliferation.

Choose Youai, Choose the Future

On the journey of immunology and tumor therapy, Youai walks hand in hand with you. Youai's IKZF1 and IKZF3 proteins, rigorously purified, offer the following advantages:

• High Purity and High Activity: Youai's IKZF1 and IKZF3 proteins undergo rigorous purification to ensure high purity and activity, effectively supporting your experimental needs.
• Specificity: Youai's proteins exhibit high specificity, accurately recognizing and binding to target molecules, minimizing non-specific reactions.

Youai's IKZF1 and IKZF3 proteins are reliable partners for exploring the mysteries of immunology and tumor therapy, assisting you in advancing from the laboratory to the clinic and bringing new hope to patients. Choose Youai, choose the future! Together with Youai, we illuminate the path to health with the power of science!

Available Products: